David Humphreys
Senior Executive Director & Head of New Modality Therapeutics UCB
Seminars
Wednesday 30th July 2025
Drug Format Mechanisms of Action to Treat Immunoglobulin Related Diseases: FcRn & FcGR Blockers, Ig DJegraders & Sweepers
3:30 pm
• Illustrate the increasing number and diversity of current and future therapeutic modality options for immunoglobulin-related diseases
• Selected examples will be highlighted to illustrate the main axes of FcRn and FcGR blockers, immunoglobulin degrades, and antigen-specific approaches
• Overview of key assets in the clinic and late-stage pre-clinical
